A Thousand Wishes muse Valentina Ferrer

Global fashion icon and A Thousand Wishes muse Valentina Ferrer connects the fragrance's signature spirit with a wider international audience and a new generation of consumers.
Global fashion icon and A Thousand Wishes muse Valentina Ferrer connects the fragrance’s signature spirit with a wider international audience and a new generation of consumers.

The fragrance icon inspires two new scents, A Thousand Wishes Granted and A Thousand Crystal Wishes, a new solid perfume format and a holiday campaign featuring global fashion icon Valentina Ferrer

What you should know:

  • Bath & Body Works is celebrating A Thousand Wishes, one of its most-loved fragrance icons, with two new interpretations of the original scent: A Thousand Wishes Granted and A Thousand Crystal Wishes
  • The collection introduces a new solid perfume format for A Thousand Wishes and A Thousand Wishes Granted, offering consumers another way to wear and layer the fragrances.
  • A Thousand Crystal Wishes introduces a collectible new eau de parfum, embellished with crystals by Swarovski. Just 1,000 individually numbered bottles were created, a nod to the fragrance’s thousand wishes inspiration, and will be available through Bath & Body Works Drops on November 11 and at select stores while supplies last.
  • Global fashion icon and A Thousand Wishes muse Valentina Ferrer brings the fragrance’s signature spirit to a wider international audience and a new generation of consumers.
  • The launch brings Bath & Body Works’ Consumer First Formula to one of its biggest fragrance icons, pairing product upgrades and a holiday campaign with wider access through Ulta Beauty, Amazon and Drops.

COLUMBUS, Ohio, Nov. 02, 2026 (GLOBE NEWSWIRE) — This holiday, Bath & Body Works is celebrating the iconic fragrance A Thousand Wishes with the introduction of two new interpretations of the original: A Thousand Wishes Granted and A Thousand Crystal Wishes. New solid perfume formats offer another way to wear both A Thousand Wishes and A Thousand Wishes Granted, while A Thousand Crystal Wishes completes the collection with a collectible eau de parfum embellished with crystals by Swarovski. The launch comes to life through a holiday campaign featuring global fashion icon and A Thousand Wishes muse Valentina Ferrer.

The Original Favorite, A Thousand Wishes

Since its launch in 2014, A Thousand Wishes has become one of Bath & Body Works’ most enduring fragrance icons. Featuring notes of pink prosecco, sparkling quince, crystal peonies, gilded amber and amaretto crème, the fragrance is known for its sparkling character and association with celebration, making it a favorite for both gifting and everyday wear.

More than 10 years later, A Thousand Wishes continues to rank among Bath & Body Works’ most-loved fragrances. The fragrance has generated over $1 billion in total sales since launch and ranked among the brand’s top five fragrances by total shop sales in 2025.

The expansion reflects Bath & Body Works’ Consumer First Formula, including product innovation through new formats, enhanced fragrance quality through higher fragrance concentrations and expanded access through Bath & Body Works stores, Ulta Beauty and Amazon. Together, these enhancements give consumers more ways to discover, wear, and enjoy one of the brand’s most loved fragrance icons.

“A Thousand Wishes has become a Bath & Body Works icon because of its ability to evoke joy, celebration and emotional connection through fragrance,” said Mary Testa-Gough, assistant vice president of product & fragrance development at Bath & Body Works. “As we continue to invest in our most loved fragrances, we remain focused on elevating every touchpoint of the scent experience through enhanced fragrance quality, improved longevity, and innovative formats that enable consumers to build a fragrance wardrobe for every mood, moment, and ritual.”

Meet A Thousand Wishes Granted

The collection expands this season with the introduction of A Thousand Wishes Granted, a fragrance that builds on the spirit of the original while offering a new scent experience. The fragrance combines bright fruit notes of wild raspberry accord and fresh bergamot with warm, soft marshmallow musk and golden amber for a more intimate expression of the original.

Consumers will also find new ways to enjoy the collection with the introduction of solid perfume for both A Thousand Wishes and A Thousand Wishes Granted. The portable format offers a convenient way to refresh and layer the fragrances throughout the day, while the dermatologist-approved* formula glides onto skin with a lightweight feel.

The collection also features enhancements across select fragrance and body care products, including higher fragrance concentrations in fine fragrance mist and eau de parfum for longer-lasting wear, along with refreshed packaging.

Embellished with Swarovski® Crystals: A Thousand Crystal Wishes

A Thousand Crystal Wishes brings the most elevated expression to the collection, featuring notes of sparkling raspberry, sugared jasmine, crystal muguet, pink patchouli and sheer woods, the limited-edition eau de parfum was crafted with the highest fragrance load in the Bath & Body Works portfolio, creating a rich and long-lasting fragrance experience. Presented in an individually numbered bottle, the limited-edition eau de parfum is designed as both a fragrance and collectible keepsake, complete with a removeable bow charm, embellished with Swarovski Crystals, extending the experience beyond the fragrance itself.

In a nod to the fragrance’s a thousand wishes inspiration, only 1,000 individually numbered bottles were created. The limited-edition fragrance will launch on 11/11, a date chosen to reinforce the collection’s wish-inspired storytelling. A Thousand Crystal Wishes will be available through Bath & Body Works Drops and at select stores.

Celebrating the Magic of a Wish: Introducing A Thousand Wishes Muse Valentina Ferrer

Brought to life through a holiday campaign starring global fashion icon and A Thousand Wishes muse Valentina Ferrer, the collection celebrates the optimism, possibility and joy that have defined the fragrance since 2014, while introducing its signature spirit to a new generation around the world.

Inspired by the idea that every wish holds possibility, the campaign captures Ferrer through a world of light, reflection and celebration, showcasing the optimism and wonder that have long defined A Thousand Wishes. Through imagery of water and movement, the creative highlights the transformative power of making a wish and embracing what comes next.

“There’s something beautiful about making a wish. It’s a moment where you allow yourself to dream without limits and imagine everything that could be ahead of you,” said Ferrer. “A Thousand Wishes by Bath & Body Works captures a sense of optimism and celebration, which makes it feel especially fitting during the holidays when you’re reflecting on wishes, dreams and the moments that matter most.”

The campaign will debut during the Latin GRAMMY Awards, including a Spanish-language adaptation of the creative, and will appear across social media, YouTube and digital platforms throughout the holiday season.

Availability

A Thousand Wishes

  • Available now at Bath & Body Works stores nationwide and online at bathandbodyworks.com.
  • Available now at Ulta Beauty stores nationwide and online at Ulta.com.
  • Available now on Amazon.
  • Available throughout the United States and Canada.
  • Products range from approximately $13 to $70.

A Thousand Wishes Granted

  • Available on Amazon beginning November 16.
  • Available throughout the United States and Canada.
  • Products range from approximately $13 to $70.

A Thousand Crystal Wishes

  • Available exclusively through Bath & Body Works Drops and in select Bath & Body Works stores.
  • Available in the United States.

Looking Ahead

  • The A Thousand Wishes franchise is expected to expand internationally beginning in spring 2027.

ABOUT BATH & BODY WORKS

Bath & Body Works is a global leader in personal care and home fragrance, driven by the belief that everybody deserves to feel good.

The brand’s beloved scents are expertly crafted for performance and a luxury fragrance experience. Formulated with thoughtfully chosen ingredients, Bath & Body Works body care products are available in multiple forms, including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, sanitizer and more. The brand’s 3-wick candles are made with high-quality fragrance oils layered throughout a premium soy wax base for up to 45 hours of room-filling fragrance.

Consumers can shop Bath & Body Works in more than 1,900 stores in the U.S. and Canada, 550-plus international locations and select Ulta Beauty stores. Online, consumers can visit bathandbodyworks.com, Amazon and Ulta.com.

*Based on review of independent testing by board-certified dermatologist

MEDIA CONTACT
communications@bbw.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3777fec3-90e6-4626-9763-3a4fe4f13a00

NESS ZIONA, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today issued a reminder, further to its announcement dated September 30, 2026, regarding the voluntary delisting of its ordinary shares, no par value per share (the “Ordinary Shares”), from trading on the Tel Aviv Stock Exchange Ltd. (“TASE”). The Company encourages holders of Ordinary Shares traded on the TASE to contact their banks or brokers to arrange for the conversion of their Ordinary Shares into American Depositary Shares (“ADSs”).

As previously announced, the last day of trading of the Ordinary Shares on the TASE will be January 1, 2027, and the Ordinary Shares will be delisted from the TASE on January 4, 2027.

The Company’s ADSs, each currently representing ninety (90) Ordinary Shares, will continue to be listed and trade on the Nasdaq Capital Market (“Nasdaq”), under the symbol “FRSX.” The voluntary delisting from the TASE will not affect the Company’s listing on Nasdaq or its reporting obligations under U.S. securities laws.

The Bank of New York Mellon (“BNY”), the depositary for the Company’s ADS program, will waive its issuance fees for the conversion of Ordinary Shares into ADSs through January 7, 2027. Beginning January 8, 2027, BNY will charge issuance fees of $5.00 per 100 ADSs delivered or a fraction thereof. The waiver applies only to BNY’s issuance fees; shareholders should consult their banks or brokers regarding any other applicable fees or charges.

A conversion guide prepared by BNY, including custodian details, required delivery instructions, issuance fees and settlement procedures, is available on the Company’s website at https://ir.foresightauto.com/wp-content/uploads/2026/11/Foresight-Conversion-Guide-Shares-to-ADSs.pdf.

Shareholders are encouraged to review the guide and contact their banks or brokers promptly to allow sufficient time to complete the conversion and benefit from BNY’s fee waiver.

To convert Ordinary Shares into ADSs, shareholders should instruct their banks or brokers to deposit the Ordinary Shares with one of BNY’s Israeli custodians identified in the conversion guide and provide complete delivery instructions. Deposits must result in the issuance of whole ADSs; deposits resulting in fractional ADSs will be rejected by the custodians.

Shareholders should confirm in advance that their receiving broker is able to accept delivery of the ADSs through The Depository Trust Company (“DTC”). Unless the Company makes special arrangements with BNY, deliveries after January 7, 2027, will be made on a delivery-versus-payment basis for the applicable issuance fees. The receiving DTC broker must accept delivery and payment of those fees for settlement to be completed.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and UAVs.

Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “aims,” “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the voluntary delisting from the TASE, the last trading day and delisting date of the Ordinary Shares on the TASE, the continued listing and trading of the ADSs on Nasdaq, and the anticipated arrangements for conversion of Ordinary Shares into ADSs, including BNY’s issuance fee waiver and subsequent issuance fees and settlement procedures. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com

All financial figures are in Canadian dollars unless otherwise noted

CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson”, or the “Company”) announced today that its Board of Directors has approved a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026. This dividend is designated as an eligible dividend for Canadian income tax purposes. For non-resident shareholders, Gibson’s dividends are subject to Canadian withholding tax.

About Gibson
Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.

Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.

For further information, please contact:

Investor Relations
Phone: (403) 776-3077
Email: investor.relations@gibsonenergy.com

Media
Phone: (403) 476-6334
Email: communications@gibsonenergy.com

Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board

Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the appointment by way of co-optation of Dr. Mehdi Shahidi as Non-Executive Independent Director to its Board of Directors, effective November 2, 2026. He replaces Dr. Paulo Fontoura, who resigned from the Board in July 2026 following his appointment as the Global Head of R&D at Sanofi SA.

“We are thrilled to welcome Mehdi to the Board. I’m confident his extensive experience in drug development, history of regulatory success, and track record of building organizations will strengthen the Board’s ability to provide strategic guidance to Lakefront as it continues to advance gamgertamig and its preclinical assets, while maintaining a disciplined approach to deploying its strategic capital,” said Gino Santini, Chair of the Board of Directors.

Biography
Dr. Mehdi Shahidi is a physician-scientist and an accomplished drug development and R&D leader with over 20 years of biopharma experience spanning translational research, clinical development, regulatory and successful introduction of innovative medicines to patients worldwide. His career combines senior leadership in global pharmaceutical R&D with entrepreneurial, venture capital, and board-level experience. He is currently Head of Development and Chief Medical Officer at Ottimo Pharma, Venture Partner at Medicxi, and a founder of Petalion Therapeutics. Previously, Dr. Shahidi served as SVP, Global Head of Medicine and CMO at Boehringer Ingelheim, where he led a large, global organization with a broad therapeutic mandate. During his tenure, he provided strategic and scientific oversight across a diverse portfolio of drug development programs, from early clinical development through multiple successful global regulatory approvals across various therapeutic areas. Dr. Shahidi previously served on the Supervisory Board of CureVac through its acquisition by BioNTech, as well as on the Innovation Committees of EFPIA and TransCelerate and the PhRMA R&D Leadership Forum. A clinical oncologist and GMC-registered specialist in pharmaceutical medicine, Dr. Shahidi completed his oncology training at the Royal Marsden Hospital and conducted clinical research at the Institute of Cancer Research, London.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations

Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements
This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as “will,” “long-term,” and “forward,” and any similar expressions. These statements include, but are not limited to, statements regarding the appointment of a new director, the expected benefits associated with the changes to Lakefront’s Board, and Lakefront’s ability to deliver meaningful impact for patients and sustainable value for shareholders. Any forward-looking statements in this press release are based on Lakefront’s management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties and other factors which might cause Lakefront’s actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties and other factors include, without limitation, the risk that Lakefront may not be able to realize the expected benefits from the appointment of the new director. A further list and description of these risks, uncertainties and other factors can be found in Lakefront’s filings and reports with the Securities and Exchange Commission (SEC), including in Lakefront’s most recent annual report on Form 20-F filed with the SEC, as supplemented and/or modified by any other filings and reports that Lakefront has made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if Lakefront’s results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. Lakefront expressly disclaims any obligation to update any forward-looking statements in this press release, unless required by law or regulation.

Attachment

– Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition –

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.

Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax’s financial and capital strategy during an important period in the Company’s history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company’s pipeline and innovative R&D platform.

“On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,” said Michael A. Metzger, Chief Executive Officer of Syndax. “Keith was integral to Syndax’s transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success.”

Mr. Metzger continued, “We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”

“I am thrilled to join Syndax at such a pivotal moment in the Company’s evolution,” said Aaron A. Ondrey. “Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company’s leadership position and its strong financial foundation.”

“It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team,” said Keith A. Goldan, Chief Financial Officer of Syndax. “I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future.”

Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company’s financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI® and played a key role in the company’s acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

All financial figures are in Canadian dollars unless otherwise noted

CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today its financial and operating results for the three and nine months ended September 30, 2026.

  Key Highlights:

  • Delivered record adjusted EBITDA(1) of $193 million and record adjusted EBITDA per share, reflecting strong performance across both Infrastructure and Marketing
  • Generated record Infrastructure adjusted EBITDA(1) of $177 million and record Infrastructure adjusted EBITDA per share, driven primarily by a full quarter of contributions from the Chauvin Infrastructure Assets
  • Achieved Marketing adjusted EBITDA(1) of $35 million, supported by continued strength in refined product margins, the benefits of a more diversified product mix, and improved crude marketing opportunities
  • Sanctioned the Chauvin pipeline expansion, which will increase system capacity by approximately 50%, supported by strong commercial interest and growing production in the Mannville, with an expected in-service date during the first half of 2028
  • Continued our industry-leading safety performance, surpassing 500 days without a recordable injury while safely bringing the Wink-to-Gateway Integration Project into service and completing the integration of the Chauvin assets into our operations
 
     

“Gibson delivered an exceptional third quarter, with record results across the business,” said Curtis Philippon, President & Chief Executive Officer. “Chauvin continues to exceed our expectations, and we are pleased to sanction an expansion that will increase pipeline capacity by approximately 50%. It is a great example of the kind of disciplined infrastructure investment we want to make: supported by our customers, closely connected to our existing assets and capable of delivering attractive returns. In the U.S., we also placed our Wink-to-Gateway Integration Project into service, enhancing connectivity across our network and positioning Gateway to capture additional volumes. With improving Canadian market access and growing producer activity, the opportunity set in front of Gibson is as strong as we have seen in some time. We are well positioned to turn those opportunities into meaningful growth and long-term value for shareholders.”

Financial Highlights:

  • Infrastructure adjusted EBITDA(1) of $177 million in the third quarter, a $23 million increase from the third quarter of 2025, primarily driven by strong performance from the Chauvin Infrastructure Assets, higher overall throughput, including record volumes moved to TMX through Edmonton, ongoing optimization of our existing assets, and benefits from the Company’s 2026 restructuring initiatives
  • Marketing adjusted EBITDA(1) of $35 million in the third quarter, a $28 million increase from the third quarter of 2025, primarily driven by strong refining margins resulting from elevated crack spreads, highlighting the benefits of the Company’s product diversification strategy
  • Adjusted EBITDA(1) on a consolidated basis of $193 million in the third quarter, a $46 million increase from the third quarter of 2025, primarily reflecting stronger Infrastructure and Marketing results and adjustments for unrealized gains and losses on financial instruments in both periods, partially offset by higher General and Administrative costs
  • Net income of $77 million in the third quarter, a $31 million increase from the third quarter of 2025, primarily due to the factors affecting segment adjusted EBITDA as noted above, partially offset by higher income tax expense and finance costs
  • Distributable Cash Flow(1) of $120 million in the third quarter, a $34 million increase from the third quarter of 2025, primarily due to the factors contributing to higher adjusted EBITDA as noted above, partially offset by higher finance cost and current income tax expense
  • Dividend payout ratio(2) of 82% and net debt to adjusted EBITDA(2) ratio of 3.9x on a trailing twelve-month basis, with both metrics expected to improve as a full 12 months of contributions from the Chauvin acquisition are reflected

Strategic Developments and Highlights:

  • In November, the Board declared a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026
  • In October, placed the Wink-to-Gateway Integration Project into service, enhancing connectivity and operational flexibility at Gateway
  • In September, the Company’s NCIB was renewed for an additional one-year period, enabling the Company to repurchase and cancel up to 7,251,988 common shares, representing 5% of the Company’s public float
  • In July, the Company closed its offering of $400 million 4.45% senior unsecured medium-term notes due January 9, 2034

(1) Adjusted EBITDA and distributable cash flow are non-GAAP financial measures. See the “Specified Financial Measures” section of this release.
(2) Net debt to adjusted EBITDA ratio and dividend payout ratio are non-GAAP financial ratios. See the “Specified Financial Measures” section of this release.

Management’s Discussion and Analysis and Financial Statements 
The 2026 third quarter Management’s Discussion and Analysis and unaudited Condensed Consolidated Financial Statements provide a detailed explanation of Gibson’s financial and operating results for the three months and nine months ended September 30, 2026, as compared to the three months and nine months ended September 30, 2025. These documents are available at www.gibsonenergy.com and on SEDAR+ at www.sedarplus.ca.

Earnings Conference Call & Webcast Details
A conference call and webcast will be held to discuss the 2026 third quarter financial and operating results at 8:00am ABT (9:00am ET) on Tuesday, November 3, 2026.

To register for the call, view dial-in numbers, and obtain a dial-in PIN, please access the following URL:

https://register-conf.media-server.com/register/BI8015be24fb1e49ffb93a019531a832fd?utm

Registration at least five minutes prior to the conference call is recommended.

This call will also be broadcast live on the Internet and may be accessed directly at the following URL:

https://edge.media-server.com/mmc/p/h5qy8qeq

The webcast will remain accessible for a 12-month period at the above URL.

Supplementary Information
Gibson has also made available certain supplementary information regarding the 2026 third quarter financial and operating results, available at www.gibsonenergy.com.

About Gibson
Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.

Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.

Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information and statements (collectively, “forward-looking statements”). All statements other than statements of historical fact are forward-looking statements. The use of any of the words “expect”, “will” and similar expressions are intended to identify forward-looking statements. Forward-looking statements included or referred to in this press release include, but are not limited to, statements concerning: the development, construction and completion of the Chauvin pipeline expansion project, including its expected increase in system capacity and anticipated in-service date; Gibson’s long-term growth strategy and ability to create long-term shareholder value, including through infrastructure investments capable of delivering attractive returns; Gateway’s positioning to capture additional volumes following the completion of the Wink-to-Gateway Integration Project; improving Canadian market access and growing producer activity, and Gibson’s ability to realize on opportunities relating thereto to produce meaningful growth and create long term value for shareholders; expectations regarding the Company’s dividend payout ratio and net debt to adjusted EBITDA metrics, including their expected improvement and the expected timing and payment of the quarterly dividend. These statements are based on assumptions that the Chauvin pipeline expansion will proceed on the anticipated schedule and within expected costs, with necessary approvals and customer support; that Canadian market access and producer activity will continue to support growth opportunities; that the Chauvin Infrastructure Assets will contribute to Gibson’s financial results as expected; and that customer demand and market conditions will support Gateway’s ability to capture additional volumes as expected. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. These statements speak only as of the date of this press release. The Company does not undertake any obligations to publicly update or revise any forward-looking statements except as required by securities law. Actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks and uncertainties including, but not limited to, construction delays or cost overruns on the Chauvin pipeline expansion, changes in producer activity, customer demand or market access, and lower-than-expected contributions from the Chauvin Infrastructure Assets, as well as the risks and uncertainties described in “Forward-Looking Information” and “Risk Factors” included in the Company’s Annual Information Form dated February 17, 2026, and Management’s Discussion and Analysis dated November 2, 2026, as filed on SEDAR+ and available on the Gibson website at www.gibsonenergy.com.

For further information, please contact:

Investor Relations
Phone: (403) 776-3077
Email: investor.relations@gibsonenergy.com

Media
Phone: (403) 476-6334
Email: communications@gibsonenergy.com

Specified Financial Measures
This press release refers to certain financial measures that are not determined in accordance with GAAP, including non-GAAP financial measures and non-GAAP financial ratios. Readers are cautioned that non-GAAP financial measures and non-GAAP financial ratios do not have standardized meanings prescribed by GAAP and, therefore, may not be comparable to similar measures presented by other entities. Management considers these to be important supplemental measures of the Company’s performance and believes these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in industries with similar capital structures.

For further details on these specified financial measures, including relevant reconciliations, see the “Specified Financial Measures” section of the Company’s MD&A for the three and nine months ended September 30, 2026 and 2025, which is incorporated by reference herein and is available on Gibson’s SEDAR+ profile at www.sedarplus.ca and Gibson’s website at www.gibsonenergy.com.

        a)    Adjusted EBITDA

Noted below is the reconciliation to the most directly comparable GAAP measures of the Company’s segmented and consolidated adjusted EBITDA for the three and nine months ended September 30, 2026, and 2025:

Three months ended September 30, Infrastructure Marketing Corporate and Adjustments Total
($ thousands) 2026 2025 2026   2025 2026   2025   2026   2025  
                 
Segment profit 174,134 149,101 43,589   4,403 —   —   217,723   153,504  
Unrealized loss (gain) on derivative financial instruments 1,372 3,503 (9,063 ) 2,339 —   —   (7,691 ) 5,842  
General and administrative — — —   — (17,997 ) (13,298 ) (17,997 ) (13,298 )
Adjustments to share of profit from equity accounted investee 1,568 1,549 —   — —   —   1,568   1,549  
Renewable virtual power purchase agreement — — —   — (715 ) (520 ) (715 ) (520 )
Adjusted EBITDA 177,074 154,153 34,526   6,742 (18,712 ) (13,818 ) 192,888   147,077  

Nine months ended September 30, Infrastructure Marketing Corporate and Adjustments Total
($ thousands) 2026 2025   2026   2025   2026   2025   2026   2025  
                 
Segment profit 491,016 459,820   60,235   27,331   —   —   551,251   487,151  
Unrealized loss (gain) on derivative financial instruments 6,751 (2,177 ) (7,825 ) (12,816 ) —   —   (1,074 ) (14,993 )
General and administrative — —   —   —   (52,668 ) (40,638 ) (52,668 ) (40,638 )
Adjustments to share of profit from equity accounted investee 4,690 3,896   —   —   —   —   4,690   3,896  
Executive transition costs — —   —   —   —   2,405   —   2,405  
Renewable virtual power purchase agreement — —   —   —   (1,732 ) (2,142 ) (1,732 ) (2,142 )
Adjusted EBITDA 502,457 461,539   52,410   14,515   (54,400 ) (40,375 ) 500,467   435,679  

  Three months ended September 30,
 
($ thousands) 2026   2025  
     
Net Income 77,026   45,694  
     
Income tax expense 27,302   12,439  
Depreciation, amortization, and impairment charges 48,905   43,398  
Finance costs, net 39,621   35,094  
Unrealized (gain) loss on derivative financial instruments (8,190 ) 5,842  
Unrealized loss (gain) on renewable virtual power purchase agreement 73   (1,436 )
Share-based compensation 5,210   4,104  
Acquisition and integration costs 970   —  
Adjustments to share of profit from equity accounted investee 1,568   1,549  
Corporate foreign exchange loss and other 403   393  
Adjusted EBITDA 192,888   147,077  

  Nine months ended September 30,
 
($ thousands) 2026   2025  
     
Net Income 158,558   156,346  
     
Income tax expense 52,245   46,580  
Depreciation, amortization, and impairment charges 145,860   128,923  
Finance costs, net 113,567   103,329  
Unrealized gain on derivative financial instruments (1,573 ) (14,993 )
Unrealized gain on renewable virtual power purchase agreement (22 ) (9,180 )
Share-based compensation 14,306   11,826  
Restructuring costs 8,125   —  
Acquisition and integration costs 6,162   —  
Adjustments to share of profit from equity accounted investee 4,690   3,896  
Corporate foreign exchange (gain) loss and other (1,451 ) 6,547  
Executive transition costs —   2,405  
Adjusted EBITDA 500,467   435,679  

        b)    Distributable Cash Flow

The following is a reconciliation of distributable cash flow from operations to its most directly comparable GAAP measure, cash flow from operating activities:

  Three months ended September 30,
  Nine months ended September 30,  
($ thousands) 2026   2025   2026   2025  
         
Cash flow from operating activities 212,583   195,572   429,766   416,804  
Adjustments:        
Changes in non-cash working capital and taxes paid (24,418 ) (50,826 ) 42,825   7,526  
Replacement capital (14,629 ) (12,863 ) (37,448 ) (33,326 )
Cash interest expense, including capitalized interest (37,486 ) (33,413 ) (107,074 ) (97,341 )
Acquisition and integration costs 970   —   6,162   —  
Restructuring costs (1) —   —   6,125   —  
Executive transition costs (1) —   —   —   2,405  
Lease payments (6,780 ) (5,353 ) (19,889 ) (18,448 )
Current income tax (10,579 ) (7,567 ) (30,821 ) (20,016 )
Distributable cash flow 119,661   85,550   289,646   257,604  

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
     
Cash flow from operating activities 523,121   484,080  
Adjustments:    
Changes in non-cash working capital and taxes paid 88,231   61,504  
Replacement capital (51,962 ) (45,053 )
Cash interest expense, including capitalized interest (141,405 ) (129,272 )
Acquisition and integration costs (1) 6,162   —  
Restructuring costs (1) 6,125   —  
Executive transition costs (1) —   8,709  
Lease payments (27,059 ) (24,511 )
Current income tax (34,071 ) (26,701 )
Distributable cash flow 369,142   328,756  
         

(1)        Costs adjusted on an incurred basis.

        c)    Dividend Payout Ratio

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
Distributable cash flow 369,142   328,756  
Dividends declared 303,342   278,095  
Dividend payout ratio 82 % 85 %

        d)    Net Debt To Adjusted EBITDA Ratio

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
     
Current and long-term debt 2,932,035   2,677,669  
Lease liabilities 106,468   51,395  
Less: unsecured hybrid notes (450,000 ) (450,000 )
Less: cash and cash equivalents (92,816 ) (58,460 )
     
Net debt 2,495,687   2,220,604  
Adjusted EBITDA 645,475   565,361  
Net debt to adjusted EBITDA ratio 3.9   3.9  
     
Infrastructure segment EBITDA 662,955   608,468  
Less:    
General and administrative (68,038 ) (52,685 )
Executive transition costs —   8,709  
Renewable virtual power purchase agreement (2,462 ) (2,855 )
  592,455   561,636  
Infrastructure leverage 4.2   4.0  

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on November 2, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com 

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com 

– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –

– Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in new patients – 

– Niktimvo™ (axatilimab-csfr) net revenue of $67.4 million in 3Q26, a 47% y/y increase, resulting in Syndax collaboration revenue of $22.6 million –

– New revumenib data expected in 4Q26 from clinical trials and real-world studies spanning the acute leukemia treatment continuum and multiple genetic subtypes –

– Company to host a conference call today at 4:30 p.m. ET –

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided a business update.

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting. We continue to have the dominant share of new patients across all age groups starting a menin inhibitor and the vast majority of revenue for the class, underscoring our position as the market leader. Importantly, a growing number of both R/R KMT2Ar and NPM1m patients are proceeding to a stem cell transplant after receiving Revuforj and then resuming therapy afterward, a dynamic that positions the business for long-term growth as the average duration of therapy extends,” said Michael A. Metzger, Chief Executive Officer.

Mr. Metzger continued, “We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity. With growing revenue from two medicines, a robust pipeline generating multiple blockbuster opportunities, world-class R&D capabilities, and a strong balance sheet, Syndax is poised to deliver long-term value.”

Recent Business Highlights and Anticipated Milestones

Revuforj® (revumenib)

  • Achieved $60.7 million in Revuforj net revenue in the third quarter of 2026, a 90% increase over the third quarter of 2025 and an 11% increase over the second quarter of 2026. New patients and total prescriptions increased by approximately 20% and 13%, respectively, in the third quarter of 2026 compared to the second quarter of 2026. The double-digit growth in net revenue, new patients, and total prescriptions reflects robust uptake in both Revuforj indications and a growing number of relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) and NPM1-mutated (NPM1m) patients proceeding to hematopoietic stem cell transplant (HSCT) and then resuming therapy in the post-transplant setting.
    • Claims data indicate that approximately 50% of R/R KMT2Ar patients proceed to HSCT after receiving Revuforj, of which about 60% have resumed therapy post-transplant. Notably, the data also indicate that approximately 40% of R/R NPM1m patients proceed to HSCT after receiving Revuforj, of which about 50% have resumed therapy post-transplant.
  • In October 2026, Revuforj received the Best Product for Rare/Orphan Diseases award from The Galien Foundation, one of the world’s most prestigious awards for biomedical research and innovation. Additionally, Revuforj was named as one of TIME’s Best Inventions of 2026 in the Medical and Healthcare category.
  • The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:
    • Frontline data from the BEAT AML trial of revumenib in combination with venetoclax/azacitidine in NPM1m and KMT2Ar acute myeloid leukemia (AML)
    • Frontline data from the SAVE trial of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in NPM1m, KMT2Ar, or NUP98-rearranged (NUP98r) AML
    • Frontline data from a Phase 1 trial of revumenib in combination with intensive chemotherapy in NPM1m, KMT2Ar, or NUP98r AML
    • Post-transplant maintenance data
    • Real-world evidence from multiple centers
    • Data from INTERCEPT, a Phase 1 trial evaluating revumenib as pre-emptive therapy for measurable residual disease (MRD) or early relapse among patients with NPM1m or KMT2Ar AML
  • The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.
  • Published preclinical revumenib data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of myelofibrosis (MF), in Cancer Cell in July 2026. These data provide the basis for the Company’s plans to develop SNDX-62122, an internally developed, next-generation menin inhibitor, for MF.
  • Multiple clinical trials evaluating revumenib across the acute leukemia treatment continuum are ongoing, such as:
    • EVOLVE-2: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed NPM1m (primary efficacy analysis population) and KMT2Ar AML patients who are unfit for intensive chemotherapy. The trial is being conducted in collaboration with the HOVON network, a leading cooperative clinical trial group with extensive experience studying novel therapies for hematologic malignancies.
    • REVEAL-ND: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1m AML patients.
    • SAVE: A Phase 1/2 trial evaluating an all-oral combination of revumenib with venetoclax and decitabine/cedazuridine in pediatric and adult patients with newly diagnosed and R/R AML or mixed-lineage acute leukemia harboring either NPM1m, KMT2Ar, or NUP98r alterations. The trial is being conducted by investigators from MD Anderson Cancer Center.
    • Intensive chemotherapy: Two ongoing Phase 1 trials evaluating the combination of revumenib with intensive chemotherapy (7+3) in newly diagnosed NPM1m or KMT2Ar acute leukemia patients.
    • BEAT AML: A Phase 1b trial evaluating the combination of revumenib with venetoclax and azacitidine in newly diagnosed older adults (≥60 years) with NPM1m or KMT2Ar AML. The trial is being conducted as part of the Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial.
    • Post-transplant maintenance: A Phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance in patients with KMT2Ar or NPM1m acute leukemia. The trial is being conducted by investigators from the City of Hope Medical Center.
    • Break Through Cancer: A Phase 2 trial studying whether the combination of revumenib and venetoclax can eliminate MRD in patients with AML and extend progression-free survival. The trial is being conducted by Break Through Cancer, a collaboration between leading U.S. cancer research centers.
    • INTERCEPT: A Phase 1 trial evaluating the use of novel therapies, including revumenib, to target MRD and early relapse in AML. The trial is being conducted by the Australasian Leukaemia and Lymphoma Group as part of the INTERCEPT AML master clinical trial.
  • The Company expects the RAVEN trial to initiate in the fourth quarter of 2026. RAVEN is a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy.
  • The Company expects the MenTain Phase 2 trial to initiate in the first quarter of 2027. MenTain will be the first randomized, placebo-controlled trial specifically focused on evaluating revumenib as post-transplant maintenance.

Niktimvo™ (axatilimab-csfr)

  • Achieved $67.4 million in Niktimvo net revenue in the third quarter of 2026, a 47% increase over the third quarter of 2025 and a 12% increase over the second quarter of 2026. Syndax and Incyte are co-commercializing Niktimvo. Syndax records 50% of the Niktimvo net commercial profit, defined as net product revenue minus the cost of sales and commercial expenses. Syndax’s share of the Niktimvo product contribution, reported as collaboration revenue, was $22.6 million in the third quarter of 2026.
  • In October 2026, data supporting the safety and feasibility of reduced-frequency dosing of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (GVHD) were published in Blood Advances. Data from the pivotal AGAVE-201 trial show that transition from axatilimab 0.3 mg/kg every two weeks to 0.6 mg/kg every four weeks was feasible and well tolerated. Patients had a prolonged duration of therapy after the switch (median of 21 months), and 84% remained on treatment as of the data cutoff, suggesting ongoing clinical benefit.
  • Two trials evaluating axatilimab in patients with newly diagnosed chronic GVHD are ongoing, including a Phase 2 trial in combination with ruxolitinib and a Phase 3 trial in combination with corticosteroids.
    • The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027.
    • The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.
  • In October 2026, the Company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new safety signals identified. Based on the results observed, Syndax does not plan to move forward with further development of axatilimab in IPF. The results from the MAXPIRe trial do not affect ongoing trials of axatilimab in other potential indications.

Pipeline Assets

SNDX-4321

  • In July 2026, the Company announced the expansion of its pipeline with SNDX-4321, a mutant-selective, CNS-penetrant, allosteric EGFR inhibitor. SNDX-4321 is in development for non-small cell lung cancer (NSCLC) patient populations with significant unmet needs, such as those with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current therapies. In contrast to ATP-site directed third- and fourth-generation EGFR inhibitors, SNDX-4321 is a novel allosteric inhibitor which binds at a pocket adjacent to the ATP site that is only accessible in the presence of L858R and certain other EGFR mutations.
  • The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.

SNDX-62122

  • In July 2026, the Company announced the selection of SNDX-62122, a next-generation menin inhibitor, for development in MF. SNDX-62122 is the first candidate from a library of internally developed, wholly owned next-generation menin inhibitors that the Company intends to advance into new areas.
  • The Company expects to submit an IND and initiate a Phase 1 trial of SNDX-62122 in MF in the fourth quarter of 2027. The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027.

Corporate Updates

  • On November 2, 2026, the Company announced Keith Goldan’s decision to retire from his role as Chief Financial Officer and the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions. 

Third Quarter 2026 Financial Results

As of September 30, 2026, Syndax had cash, cash equivalents, and short- and long-term investments of $551.1 million and 90.0 million common shares outstanding.

Total revenue for the third quarter of 2026 was $83.3 million, which consisted of $60.7 million in Revuforj net revenue and $22.6 million in Niktimvo collaboration revenue. The Niktimvo collaboration revenue is derived from the $67.4 million in Niktimvo net revenue that was previously reported by the Company’s partner Incyte for the third quarter 2026. Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and commercial expenses.

Third quarter 2026 research and development expenses increased to $67.5 million from $56.3 million for the comparable prior year period. The year-over-year change was primarily the result of increased expenses associated with frontline trials evaluating revumenib in combination with standard-of-care agents in the treatment of AML.

Third quarter 2026 selling, general and administrative expenses decreased to $43.7 million from $44.9 million for the comparable prior year period. The year-over-year change was primarily the result of lower commercial expenses due to launch costs incurred in 2025 for Revuforj and Niktimvo that were not incurred in the same period in 2026.

For the three months ended September 30, 2026, Syndax reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, compared to a net loss attributable to common stockholders of $60.7 million, or $0.70 per share, for the comparable prior year period.

Financial Guidance

For the full year of 2026, the Company continues to expect total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.

Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability.

Conference Call and Webcast

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET today, November 2, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-3q26.open-exchange.net/

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Revuforj® (revumenib)

Revuforj (revumenib) is the first and only menin inhibitor that is FDA approved for the treatment of adult and pediatric patients one year and older with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.

Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.

About Niktimvo™ (axatilimab-csfr)

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).

In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD, including a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774).

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, the potential use of its product candidates to treat various cancer indications and fibrotic diseases, Syndax’s expected full year total operating expenses, including its estimated non-cash stock compensation expense, and Syndax’s expectation that its cash, cash equivalents and short-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Niktimvo is a trademark of Incyte.
All other trademarks are the property of their respective owners.

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

   
SYNDAX PHARMACEUTICALS, INC.  
(unaudited)  
CONDENSED CONSOLIDATED BALANCE SHEETS  
               
      September 30,     December 31,  
(In thousands) 2026     2025  
Cash, cash equivalents, short and long-term investments $ 551,079     $ 394,070  
Total assets $ 692,671     $ 529,706  
Total liabilities $ 709,851     $ 465,076  
Total stockholders’ (deficit) equity $ (17,180 )   $ 64,630  
               
Common stock outstanding   89,989,347       87,405,979  
Common stock and common stock equivalents*   116,512,240       103,437,561  
               
*Common stock and common stock equivalents:          
  Common stock   89,989,347       87,405,979  
  Common stock warrants (pre-funded)   –       285,714  
    Common stock and pre-funded stock warrants   89,989,347       87,691,693  
  Options to purchase common stock   13,302,121       13,128,306  
  Restricted Stock Units   3,123,422       2,617,562  
  Conversion of convertible notes   10,097,350       –  
    Total common stock and common stock equivalents   116,512,240       103,437,561  

   
SYNDAX PHARMACEUTICALS, INC.  
(unaudited)  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
                           
      Three Months Ended September 30,     Nine Months Ended September 30,  
(In thousands, except share and per share data) 2026     2025     2026     2025  
Revenue          
  Product revenue, net $ 60,743       32,007     $ 164,366       80,649  
  Collaboration revenue, net   22,555       13,864       56,584       22,975  
Total revenues   83,298       45,871       220,950       103,624  
Operating expenses:                      
  Cost of product sales $ 13,996       2,100     $ 19,837       4,264  
  Research and development   67,481       56,280       194,362       180,143  
  Selling, general and administrative   43,716       44,917       122,843       129,753  
Total operating expenses   125,193       103,297       337,042       314,160  
Loss from operations   (41,895 )     (57,426 )     (116,092 )     (210,536 )
Other (expense) income, net:                      
  Royalty interest expense   (11,812 )     (8,283 )     (35,777 )     (24,186 )
  Convertible note interest expense   (1,164 )     –       (1,719 )     –  
  Other interest expense   (2 )     –       (4 )     (6 )
  Interest income   5,593       5,269       12,900       18,402  
  Other expense   (153 )     (275 )     (777 )     (1,082 )
Total other (expense) income, net   (7,538 )     (3,289 )     (25,377 )     (6,872 )
Net loss $ (49,433 )   $ (60,715 )   $ (141,469 )   $ (217,408 )
Other comprehensive loss:                      
  Unrealized (loss) gain on marketable securities   (1,528 )     240       (2,120 )     362  
Other comprehensive loss   (50,961 )     (60,475 )     (143,589 )     (217,046 )
Net loss per share:                      
Basic and diluted loss per share attributable to common stockholders $ (0.55 )   $ (0.70 )   $ (1.59 )   $ (2.51 )
                           
Weighted-average common shares used in calculating:                      
Basic and diluted loss per share attributable to common stockholders   89,789,842       86,620,992       89,017,885       86,531,218  

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Viper Energy, Inc. (NASDAQ:VNOM) (“Viper,” “we,” “our” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the third quarter ended September 30, 2026.

THIRD QUARTER FINANCIAL HIGHLIGHTS

  • Net income of $300 million; Net income margin of 45%
  • Adjusted EBITDA1 of $596 million; Adjusted EBITDA margin1 of 90%
  • Cash flows from operating activities of $447 million; Operating cash flow margin of 68%
  • Free Cash Flow1 of $520 million; Free Cash Flow margin1 of 79%
  • Declared Q3 2026 base cash dividend of $0.50 per Class A common share
  • Repurchased approximately 2.1 million Class A shares for approximately $90 million
  • Total debt of $2.4 billion as of September 30, 2026; Net debt1 of $2.4 billion as of September 30, 2026

THIRD QUARTER OPERATIONAL HIGHLIGHTS

  • Average daily production of 69,076 bo/d (141,152 boe/d)
  • As previously announced, on July 1, 2026, completed the Riverbend Acquisition
  • On September 1, 2026, closed the previously announced 2026 Drop Down of approximately 1,000 net royalty acres in the Permian Basin from Diamondback and related subsidiaries in exchange for approximately 3.8 million OpCo units and an equivalent number of shares of Class B common stock (the “2026 Drop Down”)
  • Lease bonus income of $4 million from 21 executed leases
  • 689 total gross (19.0 net) horizontal wells turned to production
  • As of September 30, 2026, Viper’s acreage had the following ongoing development activity:
    • 104 active horizontal rigs, representing approximately 40% of the Permian Basin total
    • 1,965 gross (38.9 net) horizontal wells2 either being drilled or completed
    • 1,404 gross (36.4 net) horizontal wells2 with line-of-sight to near-term development

__________________
1 NON-GAAP DISCLOSURES – For a definition of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Free Cash Flow margin, Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.
2 Average lateral length of wells normalized to 10,000 feet.


MCELROY RANCH ACQUISITION

During the month of September, in two separate but related transactions, Viper acquired mineral and royalty interests from third-party sellers for an aggregate purchase price of approximately $529 million, subject to customary post-closing adjustments and including certain transaction costs and $49 million of deferred consideration payable in equal quarterly installments through June 2029 (collectively, the “McElroy Ranch Acquisition”). Acquisition highlights are as follows:

  • Approximately 7,359 net royalty acres located in Upton and Crane Counties
  • Concentrated ownership of an approximately 12% net royalty interest across roughly 60,000 gross acres in an expected core geologic fairway of Barnett development in the western Midland Basin
  • Asset is 96% undeveloped with an expected 40.9 net inventory locations
    • Only 21 currently producing gross (1.7 net) horizontal locations across the entire Ranch
    • Chevron operates approximately 27% of the total net inventory, including approximately 50% of net undeveloped Barnett inventory
    • Diamondback operates approximately 15% of the total net inventory
    • Concentrated nature of mineral ownership will enable potential trades to accelerate development in the coming years
  • Offsetting Barnett wells that have at least 12 months of production data indicate an average estimated ultimate recovery of approximately 80 bo/ft
  • Stable production of approximately 400 bo/d from existing vertical wells
  • Forecasted peak production on the Ranch in the range of 5,000 bo/d over the next decade

PENDING BUCKHORN ACQUISITION
On September 14, 2026, Viper entered into a definitive purchase and sale agreement to acquire certain mineral and royalty interests from a group of entities collectively called Buckhorn Minerals (the “Pending Buckhorn Acquisition”) in exchange for $280 million cash and approximately 1.8 million shares of Viper’s Class A common stock, subject to customary closing adjustments. The cash portion of the transaction is expected to be funded through a combination of cash on hand and borrowings under the Company’s revolving credit facility. The transaction is expected to close in the fourth quarter of 2026, subject to the satisfaction of customary closing conditions. Acquisition highlights are as follows:

  • 1,552 net royalty acres, substantially all of which are in the Midland Basin; approximately 80% overlap with existing Viper acreage position
  • Midland Basin primary operators include ExxonMobil (47%) and Diamondback (29%)
  • Asset is 61% undeveloped with an expected 17.4 net inventory locations
    • Approximately 20% of Midland Basin acreage in units with zero producing horizontal wells; expected to support efficient full stack development in coming years
    • 47% of net inventory in Viper’s estimation of remaining top quartile inventory in the Midland Basin, and 70% of net inventory within the top half of remaining inventory (as determined by expected internal rate of return for the respective operators)
  • Expected next 12 months’ average daily oil production of approximately 1,500 bo/d
  • Expect pro forma net debt at year end 2026 of approximately $2.4 billion, equating to pro forma leverage of approximately 1.0x last twelve months Adjusted EBITDA3

__________________
3 NON-GAAP DISCLOSURES – For a definition of Adjusted EBITDA and Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.

OTHER RECENT EVENTS AND FORWARD OUTLOOK

  • Inclusive of the Pending Buckhorn Acquisition, initiating average daily production guidance for Q4 2026 of 70,000 to 71,000 bo/d (141,500 to 143,500 boe/d)
  • Increasing average daily production guidance for full year 2026 to 67,250 to 67,750 bo/d (137,000 to 138,000 boe/d)
  • Repurchased approximately 0.4 million Class A shares in Q4 2026 (to date) for approximately $17 million

“Viper’s momentum carried through the third quarter, with average daily oil production growing more than six percent quarter over quarter on the strength of recent acquisitions and continued development activity from both Diamondback and our third-party operators. Reflecting this continued momentum, we are again increasing our full year 2026 production guidance to 67,500 barrels of oil per day at the midpoint. The quarter also marked the first under our new return of capital framework, through which we declared our increased base dividend of $0.50 per Class A share while continuing to opportunistically repurchase shares,” said Kaes Van’t Hof, Chief Executive Officer of Viper.

Mr. Van’t Hof continued, “The McElroy Ranch Acquisition and Pending Buckhorn Acquisition announced today represent the continued execution of our differentiated consolidation strategy. The acquisitions combine to extend the quality and duration of our inventory, adding nearly 60 net locations across two largely undeveloped assets. The McElroy Ranch asset brings concentrated mineral ownership in an expected core fairway of emerging Barnett development, while the Pending Buckhorn Acquisition adds high-quality Midland Basin inventory with approximately 80% overlap with our existing footprint. Notably, we funded, or expect to fund, these acquisitions primarily with cash, delivering on the commitment we made when we revised our return of capital framework to pursue accretive M&A with minimal reliance on equity. These acquisitions add years of visible development to Viper’s portfolio and reinforce the durability of our long-term per-share growth outlook.”

FINANCIAL UPDATE

Viper’s third quarter 2026 average unhedged realized prices were $87.65 per barrel of oil, $0.96 per Mcf of natural gas and $24.02 per barrel of natural gas liquids, resulting in a total equivalent realized price of $50.52/boe.

Viper’s third quarter 2026 average hedged realized prices were $86.55 per barrel of oil, $0.66 per Mcf of natural gas and $24.02 per barrel of natural gas liquids, resulting in a total equivalent realized price of $49.51/boe.

During the third quarter of 2026, the Company recorded total operating income of $661 million and consolidated net income (including non-controlling interest) of $300 million.

As of September 30, 2026, the Company had a cash balance of $10 million and total debt outstanding (excluding debt issuance costs, discounts and premiums) of $2.4 billion, resulting in net debt (as defined and reconciled below) of $2.4 billion. Viper’s outstanding long-term debt as of September 30, 2026 consisted of $500 million in aggregate principal amount of its 4.900% Senior Notes due 2030, $1.1 billion in aggregate principal amount of its 5.700% Senior Notes due 2035 and $810 million of borrowings on its revolving credit facility, leaving approximately $1.2 billion available for future borrowings and approximately $1.2 billion of total liquidity.

THIRD QUARTER 2026 CASH DIVIDEND & CAPITAL RETURN PROGRAM

Viper announced today that the Company’s Board of Directors (the “Board”) declared a base cash dividend of $0.50 per Class A common share for the third quarter of 2026, payable on November 19, 2026 to Class A common stockholders of record at the close of business on November 12, 2026.

During the third quarter of 2026, Viper repurchased approximately 2.1 million shares of the Company’s Class A common stock for an aggregate purchase price of approximately $90 million, excluding excise tax (average price of $43.01 per share).

In total, since the initiation of Viper’s common stock repurchase program on November 9, 2020 through October 30, 2026, the Company has repurchased approximately 26.1 million shares of common stock (including both Class A shares and Class B shares paired with OpCo Units) for an aggregate purchase price of approximately $844 million, excluding excise tax (average price of $32.30 per share) and has approximately $906 million remaining on its share buyback authorization. Future cash dividends and stock repurchases are at the discretion of the Board and are subject to a number of factors discussed in Viper’s reports filed with the U.S. Securities and Exchange Commission (“SEC”).

OPERATIONS UPDATE

During the third quarter of 2026, Viper estimates that 689 gross (19.0 net 100% royalty interest) horizontal wells, normalized to lateral length of 10,000 feet, with an average royalty interest of 2.8% were turned to production on its acreage position. Of these 689 gross wells, Diamondback is the operator of 123 gross wells, with an average royalty interest of 9.4%, and the remaining 566 gross wells, with an average royalty interest of 1.3%, are operated by third parties.

As of September 30, 2026, Viper’s footprint of mineral and royalty interests was approximately 98,098 net royalty acres.

Our gross well information for the third quarter ended September 30, 2026:

  Diamondback
Operated
  Third-Party
Operated
  Total
Q3 2026 horizontal wells turned to production(1):          
Gross wells  123   566   689
Net 100% royalty interest wells  11.6   7.4   19.0
Average percent net royalty interest  9.4%   1.3%   2.8%
           
Horizontal producing well count(1):          
Gross wells  4,613   21,834   26,447
Net 100% royalty interest wells  290.9   334.1   625.0
Average percent net royalty interest  6.3%   1.5%   2.4%
           
Horizontal active development well count(1):          
Gross wells  303   1,662   1,965
Net 100% royalty interest wells  17.5   21.4   38.9
Average percent net royalty interest  5.8%   1.3%   2.0%
           
Line of sight wells(1):          
Gross wells  370   1,034   1,404
Net 100% royalty interest wells  22.5   13.9   36.4
Average percent net royalty interest  6.1%   1.3%   2.6%

(1) Average lateral length normalized to 10,000 feet.

The 1,965 gross wells currently in the process of active development are those wells that have been spud and are expected to be turned to production within approximately the next six to eight months. Further in regard to the active development on Viper’s asset base, there are currently 104 gross rigs operating on Viper’s acreage, 11 of which are operated by Diamondback. The 1,404 line-of-sight wells are those that are not currently in the process of active development, but for which Viper has reason to believe that they will be turned to production within approximately the next 15 to 18 months. The expected timing of these line-of-sight wells is based primarily on permitting by third-party operators or Diamondback’s current expected completion schedule. Existing permits or active development of Viper’s royalty acreage does not ensure that those wells will be turned to production.

GUIDANCE UPDATE

Below is Viper’s guidance for the full year 2026, as well as average production guidance for Q4 2026. This guidance gives effect to the 2026 Drop Down and the McElroy Ranch Acquisition that closed during September 2026 as well as the Pending Buckhorn Acquisition that is expected to close in the fourth quarter of 2026.

   
  Viper Energy, Inc.
   
Q4 2026 Net Production – Mbo/d 70.00 – 71.00
Q4 2026 Net Production – Mboe/d 141.50 – 143.50
Full Year 2026 Net Production – Mbo/d 67.25 – 67.75
Full Year 2026 Net Production – Mboe/d 137.00 – 138.00
   
Unit costs ($/boe)  
Depreciation, Depletion and Amortization $14.75 – $17.25
Cash G&A $0.70 – $0.90
Non-Cash Share-Based Compensation $0.10 – $0.20
Net Interest Expense $1.90 – $2.40
   
Production and Ad Valorem Taxes (% of Revenue) ~7%
Cash Tax Rate (% of Pre-Tax Income Attributable to the Company)(1) 27% – 30%

(1) Pre-tax income attributable to the Company is a non-GAAP measure. We are not able to forecast the most directly comparable GAAP measure – Income (loss) before income taxes – due to the high variability and difficulty in predicting certain items that affect Income (loss) before income taxes, such as future commodity prices, pace of development and production of our mineral interests, and factors impacting the Company’s ownership of the net assets of VNOM Holding Company LLC such as repurchases of our Class A common shares, Class B common shares or VNOM Holding Company LLC’s units (OpCo Units), or conversions of our Class B common shares and/or OpCo Units to Class A common shares.

CONFERENCE CALL

Viper will host a conference call and webcast for investors and analysts to discuss its results for the third quarter of 2026 on Tuesday, November 3, 2026 at 10:00 a.m. CT. Access to the live audio-only webcast, and replay which will be available following the call, may be found here. The live webcast of the earnings conference call will also be available via Viper’s website at www.viperenergy.com under the “Investor Relations” section of the site.

About Viper Energy, Inc.

Viper is a corporation formed by Diamondback to own, acquire and exploit oil and natural gas properties in North America, with a focus on owning and acquiring mineral and royalty interests in oil-weighted basins, primarily the Permian Basin in West Texas. For more information, please visit www.viperenergy.com.

Investors and others should note that Viper announces material financial and operational information to our investors using our investor relations website (https://www.viperenergy.com/investors/overview), press releases, SEC filings and public conference calls and webcasts. The information we post through our investor relations website may be deemed material. Accordingly, investors should monitor our investor relations website in addition to following our press releases, SEC filings and public conference calls and webcasts.

About Diamondback Energy, Inc.

Diamondback is an independent oil and natural gas company headquartered in Midland, Texas focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves primarily in the Permian Basin in West Texas. For more information, please visit www.diamondbackenergy.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks, uncertainties, and assumptions that could cause the results to differ materially from such statements. All statements, other than statements of historical fact, including statements regarding Viper’s: future performance; business strategy; future operations; estimates and projections of operating income, losses, costs and expenses, returns, cash flow, and financial position; production levels on properties in which Viper has mineral and royalty interests; developmental activity by other operators; reserve estimates and Viper’s ability to replace or increase reserves; the anticipated benefits from the Sitio Acquisition or other strategic transactions (including the Riverbend Acquisition, 2026 Drop Down, McElroy Ranch Acquisition, Pending Buckhorn Acquisition or any other acquisitions or divestitures); and plans and objectives (including Diamondback’s plans for developing Viper’s acreage and Viper’s cash dividend policy and common stock repurchase program) are forward-looking statements. When used in this news release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) as they relate to Viper are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Viper believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond its control. Accordingly, forward-looking statements are not guarantees of Viper’s future performance and the actual outcomes could differ materially from what Viper expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: changes in supply and demand levels for oil, natural gas and natural gas liquids and the resulting impact on the price for those commodities; the impact of public health crises, including epidemic or pandemic diseases and any related company or government policies or actions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, or instability in the financial sector; regional supply and demand factors, including delays, curtailment delays or interruptions of production on our mineral and royalty acreage, or governmental orders, rules or regulations that impose production limits on such acreage; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change and changing political and social perspectives on climate change and other environmental, social and governance factors; risks from our cash dividend policy and uncertainties over our future dividends; restrictions on the use of water, including limits on the use of produced water by our operators and a moratorium on new produced water well permits imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; conditions in the capital, financial and credit markets, including the availability and pricing of capital for drilling and development by our limited number of operators and our ability to replace operators in time of bankruptcy or default; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services impacting our operators; the inherent uncertainties over our estimated reserves, the development of our proved undeveloped reserves or the yield from project areas on our properties; the geographical concentration of our producing properties and reserves in the Permian Basin and in a small number of producing horizons; changes in safety, health, environmental, tax and other regulations or requirements impacting us or our operators (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business from breaches of Diamondback’s information technology systems, or from breaches of information technology systems of our operators or third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities impacting our operators; severe weather conditions and natural disasters; geopolitics, regional conflicts, acts of war or terrorist acts and the governmental or military response thereto; changes in the financial strength of counterparties to the revolving credit facility and hedging contracts of our operating subsidiary; our substantial indebtedness and changes in our credit rating; failure to develop or acquire additional reserves and identify, complete or integrate acquisitions such as the Riverbend Acquisition, McElroy Ranch Acquisition or Pending Buckhorn Acquisition; our operational dependence on, and control by, Diamondback and potential conflicts of interest thereof; and other risks and factors discussed in Viper’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic filings with the SEC, including its Forms 10-K, 10-Q and 8-K, and other filings Viper makes with the SEC, which can be obtained free of charge on the SEC’s web site at http://www.sec.gov.

In light of these factors, the events anticipated by Viper’s forward-looking statements may not occur at the time anticipated or at all. Moreover, new risks emerge from time to time. Viper cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements made in this news release. All forward-looking statements speak only as of the date of this news release or, if earlier, as of the date they were made. Viper does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

 
Viper Energy, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in millions, except per share amounts, shares in thousands)
               
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Operating income:              
Oil income  $ 557     $ 332     $ 1,567     $ 774  
Natural gas income    19       15       36       40  
Natural gas liquids income    80       46       207       110  
Royalty income    656       393       1,810       924  
Lease bonus income    4       8       29       19  
Lease bonus income—related party    —       17       5       17  
Other operating income    1       —       5       —  
Total operating income    661       418       1,849       960  
Costs and expenses:              
Production and ad valorem taxes    44       27       122       65  
Depreciation, depletion, and amortization    206       182       607       373  
Impairment    —       360       —       360  
General and administrative expenses    5       6       18       12  
General and administrative expenses—related party    7       4       18       11  
Other operating expenses    —       15       4       25  
Total costs and expenses    262       594       769       846  
Income (loss) from operations    399       (176 )     1,080       114  
Other income (expense):              
Interest expense, net    (30 )     (32 )     (81 )     (60 )
Gain (loss) on derivative instruments, net    (31 )     18       (13 )     21  
Other income (expense), net    1       (33 )     (1 )     (33 )
Total other income (expense), net    (60 )     (47 )     (95 )     (72 )
Income (loss) before income taxes    339       (223 )     985       42  
Provision for (benefit from) income taxes    39       (26 )     139       2  
Net income (loss)    300       (197 )     846       40  
Net income (loss) attributable to non-controlling interest    160       (120 )     467       5  
Net income (loss) attributable to Viper Energy, Inc.  $ 140     $ (77 )   $ 379     $ 35  
               
Net income (loss) attributable to common shares:              
Basic  $ 0.72     $ (0.52 )   $ 1.99     $ 0.25  
Diluted  $ 0.72     $ (0.52 )   $ 1.99     $ 0.25  
Weighted average number of common shares outstanding:              
Basic    193,988       148,882       189,721       133,741  
Diluted    193,988       148,882       189,721       133,868  

 
Viper Energy, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in millions, except par values and share data)
       
  September 30,   December 31,
    2026       2025  
Assets      
Current assets:      
Cash and cash equivalents  $ 10     $ 13  
Royalty income receivable (net of allowance for credit losses)    496       262  
Royalty income receivable—related party    19       88  
Prepaid expenses and other current assets    43       50  
Total current assets    568       413  
Property:      
Oil and natural gas properties:      
Proved properties    10,102       9,746  
Unproved properties    5,213       4,910  
Other property, equipment and land    8       8  
Accumulated depletion, depreciation, amortization and impairment    (3,062 )     (2,455 )
Total property and equipment, net    12,261       12,209  
Deferred income taxes (net of allowances)    132       33  
Other assets    41       16  
Total assets  $ 13,002     $ 12,671  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accrued liabilities  $ 73     $ 107  
Other current liabilities    23       4  
Total current liabilities    96       111  
Long-term debt, net    2,394       2,186  
Other long-term liabilities    36       11  
Total liabilities    2,526       2,308  
Stockholders’ equity:      
Class A Common Stock, $0.000001 par value: 1,000,000,000 shares authorized; 193,043,950 shares issued and outstanding at September 30, 2026, and 170,942,687 shares issued and outstanding at December 31, 2025    —       —  
Class B Common Stock, $0.000001 par value: 1,000,000,000 shares authorized; 168,551,337 shares issued and outstanding at September 30, 2026, and 187,023,698 shares issued and outstanding at December 31, 2025    —       —  
Additional paid-in capital    5,386       4,726  
Retained earnings (accumulated deficit)    (263 )     (278 )
Total Viper Energy, Inc. stockholders’ equity    5,123       4,448  
Non-controlling interest    5,353       5,915  
Total equity    10,476       10,363  
Total liabilities and stockholders’ equity  $ 13,002     $ 12,671  

 
Viper Energy, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited, in millions)
               
  Three Months Ended September 30,   Nine Months Ended September 30,
    2026       2025       2026       2025  
Cash flows from operating activities:              
Net income (loss)  $ 300     $ (197 )   $ 846     $ 40  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:              
Provision for (benefit from) deferred income taxes    (10 )     (36 )     (15 )     (42 )
Depreciation, depletion, and amortization    206       182       607       373  
Impairment    —       360       —       360  
(Gain) loss on derivative instruments, net    31       (18 )     13       (21 )
Net cash receipts (payments) on derivatives    (13 )     11       23       23  
Other    6       38       12       42  
Changes in operating assets and liabilities:              
Royalty income receivable    (24 )     14       (223 )     (40 )
Royalty income receivable—related party    8       (25 )     69       (33 )
Accrued liabilities    (5 )     (33 )     (46 )     (40 )
Other    (52 )     (15 )     (24 )     (8 )
Net cash provided by (used in) operating activities    447       281       1,262       654  
Cash flows from investing activities:              
Acquisitions of oil and natural gas properties    (843 )     (1,205 )     (964 )     (1,484 )
Acquisitions of oil and natural gas properties—related party    —       108       (12 )     (873 )
Proceeds from sale of oil and natural gas properties    1       —       612       —  
Net cash provided by (used in) investing activities    (842 )     (1,097 )     (364 )     (2,357 )
Cash flows from financing activities:              
Proceeds from debt    960       2,350       1,480       3,090  
Repayments of debt    (245 )     (842 )     (1,275 )     (1,568 )
Net proceeds from public offering    —       —       —       1,232  
Repurchases of shares of Class A Common Stock as part of the repurchase program    (90 )     (90 )     (272 )     (100 )
Repurchases of OpCo Units as part of the repurchase program    —       —       (46 )     —  
Dividends to stockholders    (130 )     (68 )     (363 )     (228 )
Dividends to Diamondback   (138 )     (90 )     (353 )     (258 )
Dividends to other non-controlling interest    (28 )     (8 )     (73 )     (25 )
Other    (1 )     (21 )     1       (24 )
Net cash provided by (used in) financing activities    328       1,231       (901 )     2,119  
Net increase (decrease) in cash, cash equivalents and restricted cash    (67 )     415       (3 )     416  
Cash, cash equivalents and restricted cash at beginning of period    77       28       13       27  
Cash, cash equivalents and restricted cash at end of period  $ 10     $ 443     $ 10     $ 443  

 
Viper Energy, Inc.
Selected Operating Data
(unaudited)
           
  Three Months Ended
  September 30, 2026   June 30, 2026   September 30, 2025
Production Data:          
Oil (MBbls)    6,355     5,922     5,160
Natural gas (MMcf)    19,799     18,949     14,655
Natural gas liquids (MBbls)    3,331     3,147     2,412
Combined volumes (Mboe)(1)    12,986     12,227     10,015
           
Average daily oil volumes (bo/d)    69,076     65,077     56,087
Average daily combined volumes (boe/d)    141,152     134,363     108,859
           
Average prices:          
Oil ($/Bbl)  $ 87.65   $ 98.28   $ 64.34
Natural gas ($/Mcf)  $ 0.96   $ 0.05   $ 1.02
Natural gas liquids ($/Bbl)  $ 24.02   $ 23.83   $ 19.07
Combined price ($/boe)(2)  $ 50.52   $ 53.82   $ 39.24
           
Oil, hedged ($/Bbl)(3)  $ 86.55   $ 96.42   $ 63.76
Natural gas, hedged ($/Mcf)(3)  $ 0.66   $ 1.48   $ 1.77
Natural gas liquids ($/Bbl)(3)  $ 24.02   $ 23.83   $ 19.07
Combined price, hedged ($/boe)(3)  $ 49.51   $ 55.12   $ 40.04
           
Average Costs ($/boe):          
Production and ad valorem taxes  $ 3.39   $ 3.52   $ 2.70
General and administrative – cash component    0.69     0.65     0.80
Total operating expense – cash  $ 4.08   $ 4.17   $ 3.50
           
General and administrative – non-cash stock compensation expense  $ 0.23   $ 0.25   $ 0.20
Interest expense, net  $ 2.31   $ 1.96   $ 3.20
Depreciation, depletion, and amortization  $ 15.86   $ 15.95   $ 18.17

(1) Bbl equivalents are calculated using a conversion rate of six Mcf per one Bbl.
(2) Realized price net of all deducts for gathering, transportation and processing.
(3) Hedged prices reflect the impact of cash settlements of our matured commodity derivative transactions on our average sales prices.

NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN

Adjusted EBITDA and Adjusted EBITDA margin are supplemental non-GAAP (as defined below) financial measures that are used by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines Adjusted EBITDA as net income (loss) attributable to the Company, plus net income (loss) attributable to non-controlling interest (“net income (loss)”) before interest expense, net, non-cash share-based compensation expense, depreciation, depletion and amortization, impairment, non-cash (gain) loss on derivative instruments, provision for (benefit from) income taxes and other non-cash or non-recurring operating expenses. The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by total operating income. Adjusted EBITDA and Adjusted EBITDA margin are not measures of net income as determined by United States’ generally accepted accounting principles (“GAAP”). Management believes Adjusted EBITDA and Adjusted EBITDA margin are useful because they allow them to evaluate the Company’s operating performance and compare the results of its operations from period to period without regard to its financing methods or capital structure. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, net income, royalty income, cash flow from operating activities or any other measure of financial performance or liquidity presented as determined in accordance with GAAP. Adjusted EBITDA margin should not be considered as an alternative to, or more meaningful than, net income margin, gross margin, or any other measure of financial performance or liquidity presented as determined in accordance with GAAP. Certain items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historic costs of depreciable assets, none of which are components of Adjusted EBITDA or Adjusted EBITDA margin.

The following table presents a reconciliation of the GAAP financial measure of net income (loss) to the non-GAAP financial measure of Adjusted EBITDA and a reconciliation of the GAAP ratio of net income margin to the non-GAAP ratio of Adjusted EBITDA margin:

 
Viper Energy, Inc.
Adjusted EBITDA and Adjusted EBITDA margin
(unaudited, in millions)
       
  Three Months Ended
September 30, 2026
  Twelve Months Ended
September 30, 2026
Net income (loss) attributable to Viper Energy, Inc.  $ 140     $ 276  
Net income (loss) attributable to non-controlling interest    160       324  
Net income (loss)    300       600  
Interest expense, net    30       117  
Non-cash share-based compensation expense    3       10  
Depreciation, depletion, and amortization    206       841  
Impairment    —       408  
Non-cash (gain) loss on derivative instruments    18       20  
Provision for (benefit from) income taxes    39       118  
Other non-cash or non-recurring expenses    —       12  
Adjusted EBITDA    596       2,126  
Less: Adjusted EBITDA attributable to non-controlling interest    284       1,030  
Adjusted EBITDA attributable to Viper Energy, Inc.  $ 312     $ 1,096  
       
Net income margin(1)   45 %     26 %
Adjusted EBITDA margin(1)   90 %     93 %

(1) Net income margin is calculated as net income (loss) divided by total operating income of $661 million for the three months ended September 30, 2026 and $2.28 billion for the twelve months ended September 30, 2026. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total operating income.

OPERATING CASH FLOW BEFORE WORKING CAPITAL CHANGES, FREE CASH FLOW AND FREE CASH FLOW MARGIN

Operating cash flow before working capital changes, which is a non-GAAP financial measure, represents net cash provided by operating activities as determined under GAAP without regard to changes in operating assets and liabilities. The Company believes operating cash flow before working capital changes is a useful measure of the Company’s ability to generate cash to fund acquisition activities, service debt or pay dividends. The Company also uses this measure because changes in operating assets and liabilities relate to the timing of cash receipts and disbursements that the Company may not control and may not relate to the period in which the operating activities occurred.

The Company defines Free Cash Flow, which is a non-GAAP financial measure, as operating cash flow before working capital changes in excess of capital expenditures. The Company defines Free Cash Flow margin as Free Cash Flow divided by total operating income. The Company believes that Free Cash Flow and Free Cash Flow margin are useful to investors as they provide a measure to compare cash flow from operating activities across periods on a consistent basis. These measures should not be considered as alternatives to, or more meaningful than, net cash provided by operating activities as an indicator of liquidity. The Company’s computations of Free Cash Flow and Free Cash Flow margin may not be comparable to other similarly titled measures of other companies.

The following table presents a reconciliation of the GAAP financial measure of net cash provided by operating activities to the non-GAAP measure of operating cash flow before working capital changes and to the non-GAAP measure of Free Cash Flow and a reconciliation of the GAAP ratio of operating cash flow margin to the non-GAAP ratio of Free Cash Flow margin:

 
Viper Energy, Inc.
Operating cash flow before working capital changes, Free Cash Flow and Free Cash Flow margin
(unaudited, in millions)
   
  Three Months Ended
September 30, 2026
Net cash provided by operating activities  $ 447  
Changes in operating assets and liabilities    73  
Operating cash flow before working capital changes    520  
Less: Capital expenditures    —  
Free Cash Flow  $ 520  
   
Operating cash flow margin(1)    68 %
Free Cash Flow margin(1)    79 %

(1) Operating cash flow margin is calculated as net cash provided by operating activities divided by total operating income of $661 million. Free Cash Flow margin is calculated as Free Cash Flow divided by total operating income.

PRE-TAX INCOME ATTRIBUTABLE TO VIPER ENERGY, INC.

The following table presents a reconciliation of the GAAP financial measure of income (loss) before income taxes to the non-GAAP financial measure of pre-tax income attributable to the Company. Management believes this measure is useful to investors given it provides the basis for income taxes payable by the Company.

Viper Energy, Inc.
Pre-tax income attributable to Viper Energy, Inc.
(unaudited, in millions)
   
  Three Months Ended September 30, 2026
 
Income (loss) before income taxes  $ 339  
Less: Net income (loss) attributable to non-controlling interest    160  
Pre-tax income (loss) attributable to Viper Energy, Inc.  $ 179  
   
Income taxes payable by Viper Energy, Inc. for the current period  $ 49  
Effective cash tax rate attributable to Viper Energy, Inc.    27.4 %
       

NET DEBT

The Company defines the non-GAAP measure of net debt as debt (excluding debt issuance costs, discounts and premiums) less cash and cash equivalents. Net debt should not be considered an alternative to, or more meaningful than, total debt, the most directly comparable GAAP measure. Management uses net debt to determine the Company’s outstanding debt obligations that would not be readily satisfied by its cash and cash equivalents on hand. The Company believes this metric is useful to analysts and investors in determining the Company’s leverage position because the Company has the ability to, and may decide to, use a portion of its cash and cash equivalents to reduce debt.

  September 30, 2026   Net Q3 Principal Borrowings/
(Repayments)
  June 30, 2026   March 31, 2026   December 31, 2025   September 30, 2025
  (in millions)
Total debt(1)  $ 2,410     $ 715   $ 1,695     $ 1,620     $ 2,205     $ 2,640  
Cash and cash equivalents    (10 )         (77 )     (28 )     (13 )     (443 )
Net debt  $ 2,400         $ 1,618     $ 1,592     $ 2,192     $ 2,197  

(1) Excludes debt issuance costs, discounts & premiums.

DERIVATIVES

As of the date of this news release, the Company had the following outstanding derivative contracts. The Company’s derivative contracts are based upon reported settlement prices on commodity exchanges and published index prices. Crude oil derivative settlements are based on New York Mercantile Exchange (“NYMEX”) West Texas Intermediate (“WTI”) pricing and Crude Oil Brent pricing. Natural gas derivative settlements are based on NYMEX Henry Hub pricing and the regional natural gas pricing point indicated below. Basis swaps settle on the differential between the applicable benchmark price and the regional index price, and roll swaps settle on the differential between NYMEX WTI prompt-month and second-month contract prices. When aggregating multiple contracts, the weighted average contract price is disclosed.

   
  Q4 2026   Q1 2027   Q2 2027   Q3 2027   Q4 2027
Deferred Premium Puts – WTI (Cushing)   50,000       50,000       45,000       35,000       20,000  
Strike $ 50.00     $ 50.00     $ 50.00     $ 50.00     $ 50.00  
Premium $ (1.32 )   $ (1.36 )   $ (1.35 )   $ (1.35 )   $ (1.32 )
Deferred Premium Puts – WTI / Brent Basis   30,000       —       —       —       —  
Strike $ (45.00 )     —       —       —       —  
Premium $ (1.48 )     —       —       —       —  
Roll Swaps – WTI (Cushing)   15,000       —       —       —       —  
Swap Price $ 3.97       —       —       —       —  

       
    Q4 2026  
  Costless Collars – Henry Hub   60,000  
  Floor $ 2.75  
  Ceiling $ 6.64  

   
  Q4 2026   Q1 2027   Q2 2027   Q3 2027   Q4 2027
Natural Gas Basis Swaps – Waha Hub   80,000       50,000       50,000       50,000       50,000  
Swap Price $ (1.74 )   $ (1.40 )   $ (1.40 )   $ (1.40 )   $ (1.40 )
                                       

Investor Contact:

Chip Seale
+1 432.247.6218
cseale@viperenergy.com

Source: Viper Energy, Inc.; Diamondback Energy, Inc.

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) —

Diamondback Stockholders,

This letter is meant to be a supplement to our earnings release and is being furnished to the Securities and Exchange Commission (SEC) and released to our stockholders simultaneously with our earnings release. Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.

Mega Themes

Before we talk about the quarter, we would like to give you some insight into what we see as the mega-themes of the Permian Basin over the next decade, Diamondback’s potential role in those mega-themes and why our strategy will benefit Diamondback stockholders. In our mind, these three mega-themes are: increased recoveries of oil in place, gas production growth and monetization through LNG and power demand and the growing AI / power / infrastructure buildout in West Texas and the Permian Basin.

The past decade in the Permian Basin was dominated by capital efficiency improvements, resource expansion and consolidation. This resulted in more assets in the hands of larger, well-run operators turning the dream of the shale revolution into a reality, producing more consistent returns on and of capital to the stockholders that helped fund it.

While we expect to maintain consistent returns, we anticipate the next decade will look different. Upstream consolidation in the Permian will continue, albeit at a more measured pace given how much has already occurred to date. Capital efficiency will continue to improve, but the pace of above ground mechanical improvements will naturally slow relative to what has been accomplished over the last ten years. Resource expansion will continue and new zones like the Barnett and Woodford (more on that later) are exciting, but it will be tough to match the resource growth we saw from developing the Wolfcamp B as a standalone horizontal bench in 2012 in the Midland Basin to the 8+ zones we are developing today.

Therefore, we will need to do more with what we have, directly and indirectly. We will continue to improve our position by increasing working interest (and mineral interest at Viper Energy, Inc. (“Viper”), our consolidated mineral and royalty subsidiary), extending laterals through trades, grinding down costs and being prepared for M&A opportunities if or when they present themselves.

As we mentioned earlier, we are also working on being at the forefront of three Permian mega-themes:

1. Improving Recoveries

We currently estimate that we extract approximately 10% of the oil in place in the Permian Basin today. Every percentage point of incremental recovery carries significant value to our stockholders, and we are therefore very focused on improving recoveries. There are several factors that contribute to the ultimate recovery of hydrocarbons from a well, but the list below represents the main factors we are focused on.

a) Development design:
Each project Diamondback executes is designed to maximize the return the Company receives on capital while ensuring resource recovery is maximized at an appropriate incremental rate of return hurdle. Our philosophy has resulted in Diamondback’s projects generating the highest average returns relative to our peer group. These outcomes are clearly seen on slide #10 of this quarter’s investor presentation.

Broadly, our relatively higher wells per section × better per well performance ÷ the lowest cost structure in the basin = the maximum return for every dollar of capital invested. Diamondback was an early adopter of co-development in the Midland Basin, moving to this methodology in 2019 for the core zones from the Middle Spraberry to the Wolfcamp B. Co-development of 8+ benches in the Midland Basin, optimized spacing and targeting, longer laterals and creative wellbore trajectories allow us to optimize our developments while preserving the value of our remaining inventory – an advantage we believe is unmatched in the basin.

b) Completion design:
Proper completion sizing is imperative to maximizing value from each development project. The advancement of completion technology into simulfrac and continuous pumping are positive cost stories from an operational standpoint, but they have also allowed us to pursue more aggressive stage designs with tighter cluster and stage spacing to increase reservoir contact and near-wellbore fracture complexity. We believe this, combined with our efforts around advanced chemical additives, is contributing to recent well outperformance relative to previous vintages seen on slide #10 of this quarter’s investor presentation.

c) Enhanced Oil Recovery (“EOR”):
Chemical EOR has the potential to meaningfully improve recovery factors and shallow base decline rates in unconventional reservoirs. Shallowing our corporate base decline by just 1% at current capital efficiency implies drilling 10 to 15 fewer wells to maintain flat oil production, extending inventory quality and duration.

Chemical EOR makes it easier for oil to flow through the reservoir to the wellbore. We have several ongoing pilots testing various surfactant designs both in the remedial and completion phases of our operations. These pilots are in the early stages, and we have seen a wide range of outcomes from our initial tests. We will continue to learn from these tests and refine our methodologies to continuously improve, just as we did on the completion side of the business over the last fifteen years.

Our goal is and has always been to be the best at converting rock into cash flow. We have demonstrated this ability consistently over the past decade and will continue to do so moving forward. We are confident the technologies and workflows we are developing today will propel us to higher recoveries in the future and we look forward to keeping our stockholders updated on our progress.

2. Gas Production and Monetization

In the third quarter, future gas growth out of the Permian Basin received significant attention as a WhiteWater-led consortium (that includes Diamondback) reached Final Investment Decision (“FID”) on another large diameter pipeline out of the basin. This pipe is called Solitude and is set to enter service in the second half of 2029. This project consists of two twin 48″ lines able to move 4.5 bcf/d out of the Permian to Katy and Gulf Coast markets, with potential to expand to 7.5 bcf/d. While the market was surprised that another pipe reached FID this quickly after multiple announcements over the last 18 months, we were not.

As we have said many times, the Permian Basin has not tried to produce gas yet. We expect the Permian to be the largest natural gas play as well as the largest oil play in the United States in the 2030s. Gas to oil ratios will naturally continue to expand, secondary zones in both the Midland and the Delaware Basins are gassier than what operators have targeted to date and there are gas-weighted exploratory zones that have not even been tested yet given the perpetual egress issues out of this basin.

As for Diamondback’s strategy, our goal is to continue to control more of our gas further downstream to a mix of end markets, primarily feeding the Gulf Coast LNG complex. We are working to build relationships with LNG players who are long offtake and short physical molecules. There should be beneficial deals to get done with those companies in the coming years. We also believe in-basin and in-state power demand will continue to grow, driven by both behind-the-meter power development and the expansion of the Texas grid.

At the highest level, the gas theme in the Permian Basin has moved from supply-push to demand-pull, which should be beneficial to the owners of the molecule long-term and therefore Diamondback stockholders.

3. West Texas AI / Power / Infrastructure Buildout

We believe that the incremental large-scale data center development in the United States should go through West Texas and that Diamondback can be an integral part of that value chain without overstepping our core competencies. In our mind, our Company owns or has access to all the key components of data center development:

  • Fuel: We have significant natural gas reserves that we control. These can grow if needed.
  • Land: We own surface in areas conducive to development and know how to strategically grow our position.
  • Water: We are invested in and understand the water business, which is vital to our upstream business and becoming increasingly important as industrial use cases including data center and power cooling needs grow.
  • Deal Execution: We have a long track record of sourcing, structuring, financing and integrating transactions across our value chain. Since our 2012 IPO, Diamondback, along with Viper, have successfully completed approximately $60 billion in trades across dozens of transactions, and in parallel, have formed, scaled and successfully exited joint ventures in midstream and water infrastructure, creating value beyond the drillbit. In short, we know how to get deals done, upstream and non-upstream alike, that benefit our stockholders.

Therefore, we believe companies like Diamondback with credible projects will continue to rise to the top. Our hope is to build relationships and partnerships across this space that put us in the middle of the AI revolution, and we think a company like ours can add significant value to advancing this mega-theme.

We have already developed significant relationships with strong, reliable partners in working our first project. We expect these partnerships to grow, but also see room for more. West Texas has a significant amount of private land, an abundance of fuel for power and our industry (Diamondback in particular) knows how to build things with unmatched efficiency. Diamondback’s own production has grown more than 330x since 2012 – a growth rate competitive with the tech industry that is naturally intersecting with ours.

Barnett / Woodford Update

We received significant market curiosity after revealing our Barnett position in the Midland Basin earlier this year. Since that announcement, we have grown our position to 224,000 net acres, up 12% since February. We are also entering a period of increased activity in the play as we move to full-field development so we can maximize capital efficiency while honoring lease obligations.

When we revealed our position, we told our investors we needed to work the well costs down to $800 per lateral foot for the play to be competitive with our core program. We are on our way to this number, with drilling costs down over 10% per lateral foot year-to-date including a recent well below $350 per lateral foot. Completion costs have also been reduced to below $400 per lateral foot as we have moved to large pad simulfrac operations on most current and future Barnett projects.

Recent well results also continue to increase our excitement about the Barnett. Today we revealed data around our best wells in the play on slide #11 of this quarter’s investor presentation, which had previously remained private as we worked through our leasing program. This performance, combined with our improving cost structure, further strengthens our conviction in this emerging opportunity.

Governance

In September, we disclosed an agreement with our largest stockholder, SGF FANG Holdings, LP (“SGF”), to revise the stepdown thresholds for SGF’s board designation rights. In connection with SGF’s most recent stock sale that reduced its ownership below 25% and reduced its corresponding right to designate board members from four board members to two board members, we essentially agreed that SGF could continue to designate two board members for so long as it owns at least 10% of our outstanding stock.

The Diamondback Board now has 11 members, in line with S&P 500 and large-cap energy peer averages. We believe this size balances breadth of expertise with cohesion. While we have two Board members who are SGF designees and nine who are not, we feel we are one Diamondback Board with a unified strategy to drive stockholder value while ensuring our largest stockholder feels appropriately represented on the Board with two well-qualified members who collectively bring over 75 years of experience in the oil and gas industry. We believe this is best-in-class governance.

Macro Update

The macro backdrop is almost exactly as we described last quarter: highly volatile and impossible to predict. The timing of the eventual global oil supply normalization is anyone’s guess, and we therefore expect the current volatility to continue. Through this volatility, our priorities remain unchanged: execute with the best capital efficiency in the industry and allocate Free Cash Flow appropriately to maximize long-term stockholder value.

Third Quarter 2026 Operational Performance

Third quarter oil production averaged 525 MBO/d, flat with the second quarter and above the midpoint of our guidance range. Total production for the quarter averaged 1,034 MBOE/d, up 2% quarter over quarter. Third quarter cash capital expenditures were $1.03 billion, within our $950 million to $1.05 billion guidance range. With one quarter remaining, we have updated our full-year 2026 oil production guidance to ~524 MBO/d, total production guidance to ~1,015 MBOE/d; and our full-year capex guidance to approximately $3.95 billion to $4.00 billion.

Fourth quarter guidance is 518 to 528 MBO/d (1,025 to 1,045 MBOE/d) on $1.00 to $1.05 billion of capex. Our current expectation for activity in 2027 is to run five electric simulfrac fleets consistently for maximum efficiency while running enough rigs ahead of those crews to maintain the execution buffers one would expect from Diamondback.

On the drilling side, our blended cost per lateral foot rose in the quarter as the program shifted toward deeper Barnett and Wolfcamp D targets, which now make up roughly a fifth of the wells we drill. On a like-for-like basis, drilling costs per foot in each formation remain flat to lower than a year ago. In total, we drilled 105 gross wells and completed 135, with average completed lateral length up roughly 13% quarter over quarter to 13,584 feet per well. Our completion crews finished 1.86 million lateral feet, 10% more than last quarter, at a cost per lateral foot essentially flat with both the prior quarter and a year ago. These results absorbed higher diesel, sand and water costs, consistent with the inflation pressure we flagged last quarter in casing, fuel and fuel-adjacent items. Service pricing outside those categories has remained largely stable, but it is logical that inflation could build if oil prices stay in the triple digits and the Permian rig count keeps rising. We expect any increase to be more modest than the 2022 upcycle, when rig activity surged while supply chains were still recovering from the pandemic. We continue to challenge our teams to offset cost pressure with efficiency gains in the field; we expect those gains to materialize, but the net effect will depend on the macro environment.

Technology is increasingly part of how we deliver these results. Artificial intelligence continues to grow in importance to our daily operations. We now have ~500 plunger-lift wells, about a third of our current count, that run autonomously, and we expect to convert the remainder in short order. We are also in the early stages of integrating drones into our field operations where the drones can identify issues ahead of human interaction, improving human efficiency and reducing corporate downtime.

These gains are visible in our unit costs. Lease operating expense was $5.97 per BOE, flat with the second quarter and roughly 4% below the first quarter, and total cash operating expense was $10.91 per BOE, down slightly from $10.96 in the second quarter and about 3% below the first quarter. Behind those numbers is a production organization doing more work at lower unit cost: our well-maintenance teams completed 1,448 jobs, 19% more than in the second quarter, at an average cost per job roughly 10% lower. Additionally, electric submersible pump repair costs are 14% less on average. Keeping downtime and the workover backlog in check as our well count grows is what is holding lifting cost down.

Third Quarter 2026 Financial Performance

We generated $2.6 billion in net cash provided by operating activities in the third quarter, which translated to $2.1 billion of Free Cash Flow. Cash capital expenditures of $1.0 billion represented 39% of net cash provided by operating activities for the quarter and 37% year to date. Our corporate reinvestment ratio (defined as cash CAPEX divided by Operating Cash Flow Before Working Capital Changes) was 32% for both the quarter and year to date, meaning two of every three dollars of cash flow we generated this year have been converted to Free Cash Flow.

Since the Endeavor merger closed eight quarters ago, oil production per share has increased every quarter and is up 15% over that span. Year over year, oil production per share has grown 7.5% on absolute oil growth of 4%. Year over year, net cash provided by operating activities per share has grown 12.5%, and Free Cash Flow per share has grown 26%, with our diluted share count down 3%.

Capital Allocation

Earlier this year, we removed our commitment to return a minimum amount of Free Cash Flow on a quarterly basis to stockholders. Since then, we have focused on taking advantage of what the market gives us. We have repurchased $1.1 billion of notional bonds outstanding for ~$970 million (including accrued interest) this year. It is rare for an E&P to be able to do this pro-cyclically. On top of that, in 2026 through September 30, we have reduced total debt at Diamondback (excluding Viper) by approximately $1.5 billion, to $11.0 billion, and net debt at Diamondback by approximately $2.0 billion. On a consolidated basis, total debt has decreased approximately $1.3 billion and net debt approximately $1.7 billion this year through September 30.

“Ground game” has been a hot topic in the Permian Basin this year, and Diamondback has always prided itself on executing deals of all sizes. Year to date, we have executed 34 acquisitions for $406 million, adding over 28,000 net acres and 95 net locations, and closed 10 trades covering more than 20,000 net acres. While each deal is small relative to our enterprise, in aggregate they matter: this year’s ground game activity has added 1.9 million lateral feet to inventory, replacing roughly a full quarter’s worth of completed footage. Every one of these deals creates value for our stockholders through higher working interest, longer laterals and extended inventory duration – little wins that add up year in and year out.

We also saw periods of stock price weakness in the third and early fourth quarters, and we took advantage of this weakness and bought back 1.7 million shares at an average price of $186.11. As we continue to generate cash flow at what we believe are above mid-cycle commodity prices, the “top” that we use to ensure we buy back stock at an accretive value relative to mid-cycle commodity pricing and our cost of capital will continue to go up – accreting value to the stockholders long-term. On the other hand, we are also preparing our balance sheet to be able to be aggressive on stock repurchases at the appropriate time of the natural commodity cycle.

Lastly, today we announced we increased our base dividend by over 7% to $4.72 per share annually from $4.40 previously. As a reminder, base dividend growth remains a core tenet of the value proposition at Diamondback and our base dividend is now up over 9x since initiating at $0.50 per share in 2018.

In closing, we continue to execute exceptionally well on the base business. This execution and the trust we have in our team frees us up to think more strategically about the future of the Permian Basin and Diamondback’s role in that future. We gave you a glimpse into that thinking today, see exciting things on the horizon and will update our stockholders as we progress on these initiatives with the transparency you should continue to expect from us.

Thank you for your continued interest in Diamondback Energy.

Sincerely,

Kaes Van’t Hof
Chief Executive Officer and Director

Investor Contact:
Adam Lawlis
+1 432.221.7467
alawlis@diamondbackenergy.com 

Forward-Looking Statements:

This letter contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, including statements regarding Diamondback’s: future performance; business strategy; future operations (including drilling plans and capital plans); estimates and projections of revenues, losses, costs, expenses, returns, cash flow, and financial position; reserve estimates and its ability to replace or increase reserves; anticipated benefits or other effects of strategic transactions (including the 2026 drop down to Diamondback’s subsidiary, Viper Energy, Inc. (“Viper”), Viper’s Riverbend acquisition, Viper’s McElroy Ranch acquisition and Viper’s Sitio acquisition, and other acquisitions, divestitures or reorganizations); and plans and objectives of management (including plans for future cash flow from operations and for executing environmental strategies) are forward-looking statements. When used in this letter, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) as they relate to Diamondback are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Diamondback believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Diamondback’s control. Accordingly, forward-looking statements are not guarantees of future performance and Diamondback’s actual outcomes could differ materially from what Diamondback has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: geopolitics and market conditions, including changes in supply and demand levels for oil, natural gas and natural gas liquids and the resulting impact on the price for those commodities; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, and instability in the financial sector; regional supply and demand factors, including delays, curtailments or interruptions of production, or governmental orders, rules or regulations that impose production limits; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change, changing political and social perspectives on climate change and other environmental, social and governance factors, and risks from our publicly disclosed targets related to sustainability and emissions reduction initiatives; challenges in developing our existing leasehold acreage and finding, developing or acquiring additional reserves; restrictions on the use of water, including limits on the use of produced water and a moratorium on new produced water disposal well permits recently imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; conditions in the capital, financial and credit markets, including the availability and pricing of capital for acquisitions, exploration and development operations; challenges with employee retention and an increasingly competitive labor market; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services; changes in safety, health, environmental, tax and other regulations or requirements (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business and operations from breaches of our information technology systems, or from breaches of information technology systems of third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities for our oil, natural gas and natural gas liquids; failures or delays in achieving expected reserve or production levels from existing and future oil and natural gas developments, including due to operating hazards, drilling risks, or the inherent uncertainties in predicting reserve and reservoir performance; inability to keep pace with technological developments in our industry; failure to meet our obligations under our oil purchase contracts; loss of one or more customers or their inability to meet their obligations; geographical concentration of our primary operations; risks from our return of capital activity, and uncertainties over our future dividends and share repurchases; difficulty in obtaining necessary approvals and permits; severe weather conditions and natural disasters; changes in the financial strength of counterparties to our credit facilities and hedging contracts; our substantial indebtedness and restrictions to our operating and financial flexibility; changes in our credit rating; failure to identify, complete and successfully integrate acquisitions, including Viper’s Riverbend acquisition, McElroy Ranch acquisition and Sitio acquisition; the Endeavor stockholders’ ability to significantly influence our business and potential conflicts of interest; and other risks described in Part I, Item 1A of Diamondback’s Annual Report on Form 10-K, filed with the SEC on February 25, 2026, and those risks disclosed in its subsequent filings on Forms 10-Q and 8-K, which can be obtained free of charge on the SEC’s website at http://www.sec.gov and Diamondback’s website at www.diamondbackenergy.com/investors.

In light of these factors, the events anticipated by Diamondback’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Diamondback operates in a very competitive and rapidly changing environment and new risks emerge from time to time. Diamondback cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this letter or, if earlier, as of the date they were made. Diamondback does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Non-GAAP Financial Measures

This letter includes financial information not prepared in conformity with generally accepted accounting principles (GAAP), such as Free Cash Flow, Free Cash Flow per share, Operating Cash Flow Before Working Capital Changes, and net debt. The non-GAAP information should be considered by the reader in addition to, but not instead of, financial information prepared in accordance with GAAP. A reconciliation of the differences between these non-GAAP financial measures and the most directly comparable GAAP financial measures can be found in Diamondback’s quarterly results, which are posted on Diamondback’s website at www.diamondbackenergy.com/investors and included as Exhibit 99.1 to the Current Report on Form 8-K filed by Diamondback with the SEC that also includes this letter as Exhibit 99.2. Furthermore, this letter includes or references certain forward-looking, non-GAAP financial measures. Because Diamondback provides these measures on a forward-looking basis, it cannot reliably or reasonably predict certain of the necessary components of the most directly comparable forward-looking GAAP financial measures, such as future impairments and future changes in working capital. Accordingly, Diamondback is unable to present a quantitative reconciliation of such forward-looking, non-GAAP financial measures to the respective most directly comparable forward-looking GAAP financial measures. Diamondback believes that these forward-looking, non-GAAP measures may be a useful tool for the investment community in comparing Diamondback’s forecasted financial performance to the forecasted financial performance of other companies in the industry.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.